ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
From bench to knowledge graph: mapping the global evolution of PD-1/PD-L1 immunotherapy in gastric cancer.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a highly lethal gastrointestinal malignancy characterized by strong metastatic potential. Although PD-1/PD-L1 immunotherapy has been widely applied in the treatment of GC, no comprehensive bibliometric analysis has yet been conducted in this field. This study performed a comprehensive bibliometric analysis of English-language reviews and original research articles from the Web of Science Core Collection spanning January 1, 2000 to September 17, 2025. Leveraging CiteSpace, VOSviewer, and the bibliometrix package, we systematically evaluated and visualized trends in annual publication output, geographic and institutional distribution, authorship, journal performance, keyword evolution, and citation patterns within the field. Over the past two decades, research on PD-1/PD-L1 immunotherapy for GC has surged, with a total of 2,114 publications. China leads in both the number of publications and institutional contributions, with Nanjing Medical University being the top institution. The National Natural Science Foundation of China provides the largest research funding in this field. "Frontiers in Oncology" is the leading journal for this research area, with Lin Shen being the most prolific author. Among 5,190 keyword searches, "gastric cancer" was the most frequently occurring term. Notably, "gastroesophageal junction" emerged as another prominent keyword, with terms such as "gastroesophageal junction" and "PD-1 inhibitor" continuing to feature prominently in the literature. This research delineates the current research landscape and emerging trends of PD-1/PD-L1 immunotherapy for GC, offering valuable insights to researchers to discover cutting-edge directions and key research hotspots in this field.
Indexed as
Identifiers
41212277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.